Renovaro Net Tangible Assets vs Capital Stock Analysis

RENB Stock

0.77 0.07 8.33%

Renovaro Biosciences financial indicator trend analysis is much more than just breaking down Renovaro Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Renovaro Biosciences is a good investment. Please check the relationship between Renovaro Biosciences Net Tangible Assets and its Capital Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.

Net Tangible Assets vs Capital Stock

Net Tangible Assets vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Renovaro Biosciences Net Tangible Assets account and Capital Stock. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Renovaro Biosciences' Net Tangible Assets and Capital Stock is -0.61. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Renovaro Biosciences, assuming nothing else is changed. The correlation between historical values of Renovaro Biosciences' Net Tangible Assets and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Renovaro Biosciences are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Net Tangible Assets i.e., Renovaro Biosciences' Net Tangible Assets and Capital Stock go up and down completely randomly.

Correlation Coefficient

-0.61

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most indicators from Renovaro Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Renovaro Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.The current year's Selling General Administrative is expected to grow to about 29.2 M, whereas Issuance Of Capital Stock is forecasted to decline to about 2.6 M.

Renovaro Biosciences fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Common Stock Total Equity	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Short Long Term Debt Total	Net Debt	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Current Assets	Short Term Debt	Non Current Assets Total	Non Currrent Assets Other	Intangible Assets	Net Tangible Assets	Accounts Payable	Other Assets	Retained Earnings Total Equity	Capital Surpluse
Other Current Liab		0.98	0.32	-0.84	0.62	0.85	0.87	0.96	0.54	0.08	0.44	-0.33	-0.33	0.77	0.9	-0.25	-0.22	0.65	0.44	-0.2	-0.32	-0.58	0.96	-0.23	-0.49	0.39
Total Current Liabilities	0.98		0.3	-0.89	0.66	0.87	0.88	0.97	0.52	0.11	0.49	-0.36	-0.36	0.83	0.92	-0.28	-0.25	0.77	0.42	-0.22	-0.33	-0.66	0.99	-0.22	-0.54	0.43
Total Stockholder Equity	0.32	0.3		-0.41	0.79	0.67	0.64	0.52	0.95	0.87	-0.49	0.66	0.66	0.14	0.58	0.64	0.72	0.12	0.99	0.49	0.77	-0.08	0.26	0.38	-0.76	0.88
Retained Earnings	-0.84	-0.89	-0.41		-0.82	-0.92	-0.83	-0.91	-0.56	-0.38	-0.42	0.16	0.16	-0.91	-0.94	0.16	0.06	-0.86	-0.51	0.2	0.13	0.64	-0.89	0.16	0.78	-0.68
Common Stock Total Equity	0.62	0.66	0.79	-0.82		0.94	0.82	0.8	0.88	0.8	-0.06	0.35	0.35	0.65	0.89	0.29	0.44	0.62	0.83	0.14	0.43	-0.37	0.63	0.17	-0.96	0.92
Other Stockholder Equity	0.85	0.87	0.67	-0.92	0.94		0.94	0.96	0.83	0.57	0.15	0.09	0.09	0.77	0.99	0.1	0.19	0.71	0.75	0.03	0.15	-0.53	0.85	0.01	-0.86	0.79
Total Liab	0.87	0.88	0.64	-0.83	0.82	0.94		0.94	0.81	0.47	0.09	0.07	0.07	0.7	0.92	0.22	0.17	0.62	0.73	0.09	0.1	-0.65	0.85	0.02	-0.69	0.67
Common Stock	0.96	0.97	0.52	-0.91	0.8	0.96	0.94		0.71	0.33	0.32	-0.14	-0.14	0.79	0.98	-0.09	-0.03	0.72	0.62	-0.09	-0.09	-0.59	0.95	-0.11	-0.7	0.61
Total Assets	0.54	0.52	0.95	-0.56	0.88	0.83	0.81	0.71		0.81	-0.35	0.53	0.53	0.33	0.75	0.55	0.61	0.28	0.96	0.41	0.62	-0.23	0.48	0.3	-0.8	0.85
Short Long Term Debt Total	0.08	0.11	0.87	-0.38	0.8	0.57	0.47	0.33	0.81		-0.52	0.76	0.76	0.18	0.46	0.7	0.79	0.2	0.84	0.49	0.85	-0.06	0.07	0.54	-0.81	0.9
Net Debt	0.44	0.49	-0.49	-0.42	-0.06	0.15	0.09	0.32	-0.35	-0.52		-0.9	-0.9	0.53	0.29	-0.82	-0.88	0.54	-0.39	-0.75	-0.8	-0.46	0.54	-0.47	0.02	-0.22
Cash	-0.33	-0.36	0.66	0.16	0.35	0.09	0.07	-0.14	0.53	0.76	-0.9		1.0	-0.35	-0.05	0.86	0.98	-0.33	0.57	0.54	0.9	0.41	-0.42	0.48	-0.37	0.49
Cash And Short Term Investments	-0.33	-0.36	0.66	0.16	0.35	0.09	0.07	-0.14	0.53	0.76	-0.9	1.0		-0.35	-0.05	0.86	0.98	-0.33	0.57	0.54	0.9	0.41	-0.42	0.48	-0.37	0.49
Net Receivables	0.77	0.83	0.14	-0.91	0.65	0.77	0.7	0.79	0.33	0.18	0.53	-0.35	-0.35		0.81	-0.28	-0.25	0.84	0.25	-0.26	-0.32	-0.7	0.83	-0.21	-0.59	0.46
Common Stock Shares Outstanding	0.9	0.92	0.58	-0.94	0.89	0.99	0.92	0.98	0.75	0.46	0.29	-0.05	-0.05	0.81		-0.04	0.06	0.75	0.67	-0.1	0.02	-0.54	0.9	-0.06	-0.81	0.71
Non Current Liabilities Total	-0.25	-0.28	0.64	0.16	0.29	0.1	0.22	-0.09	0.55	0.7	-0.82	0.86	0.86	-0.28	-0.04		0.85	-0.3	0.58	0.62	0.84	0.03	-0.32	0.54	-0.26	0.44
Total Current Assets	-0.22	-0.25	0.72	0.06	0.44	0.19	0.17	-0.03	0.61	0.79	-0.88	0.98	0.98	-0.25	0.06	0.85		-0.25	0.64	0.53	0.89	0.34	-0.31	0.47	-0.45	0.56
Short Term Debt	0.65	0.77	0.12	-0.86	0.62	0.71	0.62	0.72	0.28	0.2	0.54	-0.33	-0.33	0.84	0.75	-0.3	-0.25		0.21	-0.29	-0.29	-0.67	0.79	-0.06	-0.58	0.45
Non Current Assets Total	0.44	0.42	0.99	-0.51	0.83	0.75	0.73	0.62	0.96	0.84	-0.39	0.57	0.57	0.25	0.67	0.58	0.64	0.21		0.44	0.68	-0.19	0.38	0.34	-0.78	0.9
Non Currrent Assets Other	-0.2	-0.22	0.49	0.2	0.14	0.03	0.09	-0.09	0.41	0.49	-0.75	0.54	0.54	-0.26	-0.1	0.62	0.53	-0.29	0.44		0.63	0.04	-0.21	0.53	-0.04	0.29
Intangible Assets	-0.32	-0.33	0.77	0.13	0.43	0.15	0.1	-0.09	0.62	0.85	-0.8	0.9	0.9	-0.32	0.02	0.84	0.89	-0.29	0.68	0.63		0.3	-0.36	0.55	-0.47	0.61
Net Tangible Assets	-0.58	-0.66	-0.08	0.64	-0.37	-0.53	-0.65	-0.59	-0.23	-0.06	-0.46	0.41	0.41	-0.7	-0.54	0.03	0.34	-0.67	-0.19	0.04	0.3		-0.71	0.1	0.27	-0.28
Accounts Payable	0.96	0.99	0.26	-0.89	0.63	0.85	0.85	0.95	0.48	0.07	0.54	-0.42	-0.42	0.83	0.9	-0.32	-0.31	0.79	0.38	-0.21	-0.36	-0.71		-0.28	-0.51	0.41
Other Assets	-0.23	-0.22	0.38	0.16	0.17	0.01	0.02	-0.11	0.3	0.54	-0.47	0.48	0.48	-0.21	-0.06	0.54	0.47	-0.06	0.34	0.53	0.55	0.1	-0.28		-0.18	0.27
Retained Earnings Total Equity	-0.49	-0.54	-0.76	0.78	-0.96	-0.86	-0.69	-0.7	-0.8	-0.81	0.02	-0.37	-0.37	-0.59	-0.81	-0.26	-0.45	-0.58	-0.78	-0.04	-0.47	0.27	-0.51	-0.18		-0.93
Capital Surpluse	0.39	0.43	0.88	-0.68	0.92	0.79	0.67	0.61	0.85	0.9	-0.22	0.49	0.49	0.46	0.71	0.44	0.56	0.45	0.9	0.29	0.61	-0.28	0.41	0.27	-0.93

Click cells to compare fundamentals

Renovaro Biosciences Account Relationship Matchups

Renovaro Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	1.3M	3.6M	723.2K	17.9M	20.6M	21.6M
Total Current Liabilities	1.9M	6.5M	11.0M	30.3M	34.9M	36.6M
Total Stockholder Equity	174.7M	72.6M	46.5M	132.0M	151.8M	78.5M
Retained Earnings	(90.9M)	(204.3M)	(244.0M)	(324.7M)	(292.2M)	(277.6M)
Other Stockholder Equity	265.6M	277.0M	290.6M	456.8M	525.3M	551.6M
Total Liab	14.9M	12.0M	11.8M	31.2M	35.8M	37.6M
Common Stock	5.2K	5.3K	6.4K	15.5K	17.8K	18.7K
Total Assets	189.6M	84.6M	58.3M	163.1M	187.6M	197.0M
Short Long Term Debt Total	7.3M	7.0M	5.6M	3.8M	4.4M	3.4M
Net Debt	(13.4M)	(2.2M)	3.7M	3.6M	3.2M	3.4M
Cash	20.7M	9.2M	1.9M	220.5K	253.5K	240.9K
Cash And Short Term Investments	20.7M	9.2M	1.9M	220.5K	253.5K	240.9K
Net Receivables	20.8K	2.0K	1.6K	1.1M	1.3M	1.3M
Common Stock Shares Outstanding	47.2M	52.5M	56.3M	96.2M	110.7M	116.2M
Liabilities And Stockholders Equity	189.6M	84.6M	58.3M	163.1M	187.6M	197.0M
Non Current Liabilities Total	13.1M	5.6M	775.6K	842.4K	968.7K	920.3K
Total Current Assets	20.9M	9.6M	2.6M	2.0M	2.3M	2.2M
Short Term Debt	292.4K	1.5M	5.0M	2.9M	3.4M	3.6M
Non Current Assets Total	168.7M	75.1M	55.7M	161.1M	185.3M	96.5M
Non Currrent Assets Other	21.0K	68.6K	21.7K	19.8K	17.9K	17.0K
Accumulated Other Comprehensive Income	(10.8K)	(30.4K)	(29.9K)	(170.8K)	(153.8K)	(146.1K)
Intangible Assets	154.9M	61.6M	42.7M	30.0K	34.5K	32.8K
Net Tangible Assets	(269.1K)	8.1M	(636.4K)	(7.8M)	(7.0M)	(6.7M)
Accounts Payable	320.6K	1.4M	5.3M	9.4M	10.9M	11.4M
Other Current Assets	232.9K	393.0K	690.9K	668.9K	602.0K	362.8K
Capital Lease Obligations	1.5M	1.2M	969.0K	1.3M	1.5M	945.9K
Net Invested Capital	180.4M	78.4M	51.1M	134.4M	154.6M	130.5M
Property Plant And Equipment Gross	2.2M	2.1M	1.9M	2.3M	2.7M	1.6M
Net Working Capital	19.0M	3.1M	(8.5M)	(28.3M)	(25.5M)	(24.2M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Renovaro Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renovaro Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renovaro Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renovaro Biosciences Stock:

How To Invest In Renovaro

Details

Is Renovaro Stock a good investment?

Details

What is Renovaro Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.46)

Return On Assets

(0.18)

Return On Equity

(1.88)

The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Renovaro Net Tangible Assets vs Capital Stock Analysis

Net Tangible Assets vs Capital Stock

Net Tangible Assets vs Capital Stock Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Capital Stock

Renovaro Biosciences fundamental ratios Correlations

Renovaro Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Renovaro Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Accounts Payable	+ 0.99	Total Current Liabilities
Non Current Assets Total	+ 0.99	Total Stockholder Equity
Common Stock Shares Outstanding	+ 0.99	Other Stockholder Equity
Total Current Liabilities	+ 0.98	Other Current Liab
Common Stock Shares Outstanding	+ 0.98	Common Stock

Retained Earnings Total Equity	- 0.96	Common Stock Total Equity
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Capital Surpluse	- 0.93	Retained Earnings Total Equity
Other Stockholder Equity	- 0.92	Retained Earnings
Net Receivables	- 0.91	Retained Earnings
Common Stock	- 0.91	Retained Earnings